Endlyz Therapeutics
Endlyz Therapeutics develops disease-modifying medicines intended to slow or halt neurodegeneration in Parkinson’s disease and other dementias. The company targets endo-lysosomal dysfunction by developing small-molecule modulators of lysosomal transporters ATP13A2 and ATP10B. Endlyz operates as a biopharmaceutical drug-discovery company that leverages academic collaborations (including KU Leuven and Oxford) and Quantum AI-enabled discovery workflows. Its lead programs focus on genetic subsets of Parkinson’s with plans to expand into sporadic forms and broader neurodegenerative indications.
Endlyz Therapeutics
Endlyz Therapeutics develops disease-modifying medicines intended to slow or halt neurodegeneration in Parkinson’s disease and other dementias. The company targets endo-lysosomal dysfunction by developing small-molecule modulators of lysosomal transporters ATP13A2 and ATP10B. Endlyz operates as a biopharmaceutical drug-discovery company that leverages academic collaborations (including KU Leuven and Oxford) and Quantum AI-enabled discovery workflows. Its lead programs focus on genetic subsets of Parkinson’s with plans to expand into sporadic forms and broader neurodegenerative indications.